While it is already known that ideal cardiovascular health is associated with lower risk of diabetes, whether this association persists across glycemic levels is unknown.
The American College of Cardiology has released new guidance on the use of therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Previous research has questioned the safety of SGLT2 inhibitors. In order to assess the association between these drugs and the risk of 7 serious adverse events, researchers conducted a propensity score...
In a meta-analysis of 19 studies, investigators compared the effects of metabolic surgery vs medical therapy on mortality and the incidence of microvascular complications in type 2 diabetes. The findings...
In type 2 diabetes, empagliflozin (EMPA) likely has beneficial renal effects regardless of patients’ level of glycemic control prior to and during therapy, according to ne
In patients with type 2 diabetes, long-term decreases in estimated glomerular filtration rate (eGFR) and increases in urine albumin-to-creatinine ratio (UACR) are associat
The European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) have released an updated consensus statement on the management of hyperglycemia in patients with type 2...
